Company news

Neuren Pharmaceuticals Limited news in 2026

Neuren Pharmaceuticals Limited's news releases, calls and decks from 2026, newest first.

View company

Q3 2026 DAYBUE net sales up 39%, full year guidance upgraded

November 4, 2026

FDA grants Orphan Drug Designation for NNZ-2591 to treat HIE

November 1, 2026

Trofinetide US patent protections extended to March 2041

September 28, 2026

Pause in Trading

September 28, 2026

Update - Dividend/Distribution - NEU

September 18, 2026

Corporate Presentation, 2 September 2026

September 1, 2026

Dividend/Distribution - NEU

August 26, 2026

Investor presentation, 26 August 2026

August 25, 2026

Growing royalty anchors Neuren first ever dividend program

August 25, 2026

Half Yearly Report and Accounts

August 25, 2026

European Commission grants marketing authorisation for DAYBU

August 24, 2026

Neuren H1 2026 Financial Results Webinar on 26 August 2026

August 21, 2026

Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded

August 4, 2026

DAYBU recommended for approval in the European Union

June 28, 2026

Q1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025

May 7, 2026

DAYBUE STIX now broadly available in US for Rett syndrome

April 8, 2026

Acadia confirms plan to request CHMP re-examination

March 2, 2026

2025 royalty income A$65m, profit after tax A$30m

February 26, 2026

Appendix 4E and 2025 full year accounts

February 26, 2026

Acadia reports DAYBUE net sales for 2025 and 2026 guidance

February 26, 2026

Pause in Trading

February 25, 2026

Neuren to commence new on-market share buy-back program

February 11, 2026

First patient dosed in Neuren PMS Phase 3 trial

February 5, 2026

Neuren receives US FDA meeting feeback for HIE and PTHS

February 4, 2026

Trading Halt

February 3, 2026

Acadia provides update on EU regulatory submission

February 2, 2026

Response to ASX Aware Letter

January 18, 2026

DAYBUE net sales projected to reach approx US$700m in 2028

January 13, 2026

Decks in 2026